Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
| Autor: | Heidar Albandar, Jasim M. Albandar, Samuel A. Merrill, Patrick C. Ma, Salahuddin Safi, Jacob Fuqua |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Immune checkpoint inhibitors Treatment outcome Lower risk lcsh:RC254-282 Article 03 medical and health sciences 0302 clinical medicine Immune system Internal medicine Medicine Adverse effect Adult patients business.industry Cancer lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Immune checkpoint rechallenge of immunotherapy checkpoint inhibitor 030220 oncology & carcinogenesis immune related adverse event business 030215 immunology |
| Zdroj: | Cancers Volume 13 Issue 5 Cancers, Vol 13, Iss 989, p 989 (2021) |
| ISSN: | 2072-6694 |
| Popis: | Introduction: There is growing recognition of immune related adverse events (irAEs) from immune checkpoint therapies being correlated with treatment outcomes in certain malignancies. There are currently limited data or consensus to guide management of irAEs with regards to treatment rechallenge. Methods: We conducted a retrospective analysis with an IRB-approved protocol of adult patients seen at the WVU Cancer Institute between 2011–2019 with a histopathologic diagnosis of active cancers and were treated with immune checkpoint inhibitors (ICI) therapy. Results: Demographics were similar between the ICI interrupted irAE groups within cancer types. Overall, out of 548 patients who received ICI reviewed, there were 133 cases of ≥1 irAE found of any grade. Being treated with anti-CTLA-4 inhibitor ICI was associated with lower risk of death compared to anti-PD-1 ICI. The overall survival difference observed for irAE positive patients, between rechallenged (37.8 months, reinitiated with/without interruption 38.6 months, reinitiated after interruption) and interrupted/non-reinitiated (i.e., discontinued) groups (24.9 months) was not statistically significant, with a numerical trend favoring the former. Conclusions: Our exploratory study did not identify significantly different survival outcomes among the Appalachian West Virginia adult cancer patients treated with ICI who developed irAE and had treatment reinitiated after interruption, when compared with those not reinitiated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|